Skip to content
Menu

Summit Therapeutics Inc. SMMT

Full chart Compare
Set alert

Price alert · SMMT

All alert types
9.95 USD -0.62 (-5.87%)

Regular-session close

10.08 +0.13 +1.31%

After hours · Nov 20, 7:42 PM ET

9.89 Day range 10.61
9.95 52-week range 26.38
YTD
-43.11%
1 year
-39.51%

5D -3.01 (-23.23%)

10111213MonTueWedThuFri9.95
Market cap
7.96B
EPS (ttm)
-1.06
Shares out
799.76M
Forward P/E
-9.44
YTD return
-43.11%
1-year return
-39.51%
50-day average
15.89
200-day average
16.08
Enterprise value
7.84B
Price / book
14.09
Volume
7.22M
Avg volume
6.68M
Open
10.26
Previous close
10.57
Day's range
9.89 – 10.61
52-week range
9.95 – 26.38
Beta
-1.52
Analysts
Buy
Price target
28.77 (+189.1%)
Earnings date
Feb 22, 2027

Key statistics

Free cash flow
-213.92M
Total cash
629.79M
Total debt
19.98M
Return on equity
-220.01%
Short % of float
26.67%

Fundamental scorecard

5 of 25 checks passed on SMMT’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SMMT Revenue — quarterly 0
SMMT Net income — quarterly -208.38M
SMMT EPS — quarterly -0.26

Earnings

SMMT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 22, 2027Dec 30, 2026-0.34———
Nov 4, 2026Sep 30, 2026-0.28174-0.26+0.02+7.72%
Jul 23, 2026Jun 30, 2026-0.27439-0.28-0.01-2.04%
Apr 30, 2026Mar 31, 2026-0.33-0.24+0.09+27.27%
Feb 23, 2026Dec 31, 2025-0.10264-0.29-0.19-182.54%
Oct 20, 2025Sep 30, 2025-0.17577-0.31-0.13-76.37%

Upgrades / downgrades

SMMT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 1, 2026BarclaysmainEqual-WeightEqual-Weight
Sep 29, 2026CitigroupmainBuyBuy
Sep 23, 2026HC Wainwright & Co.reitNeutralNeutral
Sep 9, 2026JefferiesupHoldBuy
Aug 26, 2026HC Wainwright & Co.reitNeutralNeutral
Aug 25, 2026BernsteinupUnderperformMarket Perform

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
smmttx.com

News

Your note

Sign in to keep a note on SMMT — it syncs with the Stock Master app.

Insider holders

SMMT insider holders
InsiderRelationLatest transactionDateShares held
ANAND BHASKAROfficerStock Award(Grant)Oct 7, 2026261,047
DUGGAN ROBERT WILLIAMChief Executive OfficerConversion of Exercise of derivative securityNov 15, 20260
SONI MANMEET SINGHChief Operating OfficerConversion of Exercise of derivative securityNov 15, 20263,224,380
XIA YUDirectorPurchaseOct 20, 20250
ZANGANEH MAHKAMOfficer, Director and Beneficial OwnerConversion of Exercise of derivative securityNov 15, 2026610,516,000

Institution ownership

SMMT institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP4.10%32,786,348326.22MSep 29, 2026
Blackrock Inc.1.30%10,363,750103.12MSep 29, 2026
FMR, LLC1.02%8,136,74580.96MSep 29, 2026
Vanguard Capital Management LLC0.90%7,230,44171.94MSep 29, 2026
Vanguard Portfolio Management LLC0.84%6,717,64266.84MSep 29, 2026
State Street Corporation0.76%6,093,47460.63MSep 29, 2026

Fund ownership

SMMT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.46%3,707,54836.89MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF0.45%3,635,14536.17MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund0.33%2,667,31726.54MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.32%2,531,23125.19MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund0.26%2,047,86220.38MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.22%1,778,36117.69MJun 29, 2026